Wall Street is ditching amyloid-based Alzheimer’s drugs. They shouldn't, scientists say
March 25, 2019 at 12:38 PM EDT
Wall Street analysts, reacting to a string of Alzheimer’s drug failures, are telling investors that it’s time to ditch amyloid-based treatments. But scientists don’t agree.
